ThermoGenesis Holdings, Inc. (Nasdaq:THMO), formerly known as Cesca Therapeutics Inc., is a pioneer and market leader in the development and commercialization of automated cell processing technologies for the cell and gene therapy field. ThermoGenesis Corp., a subsidiary of ThermoGenesis Holdings, Inc., markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and large scale cell processing and manufacturing for the emerging CAR-T immunotherapy market.
For more than two decades ThermoGenesis Holdings, Inc. has developed and commercialized novel cell processing systems and devices providing global researchers, biomanufacturing organizations and clinicians with highly efficient cell processing devices which helped them to deliver better outcomes in various applications in the cell and gene therapy field.
1987: ThermoGenesis Corp. (originally named Instacool Inc.) founded by Philip Coelho, in Rancho Cordova, CA.
1989: Launched the Thermoline® ultra-rapid blood plasma freezer and thawer product lines.
1996: Launched the Cord Blood Transfer/Freezing Bag set, co-developed with New York Blood Center (NYBC) for cord blood processing.
2005: Released the AutoXpress System (AXP®), to automate the cell processing and harvesting of hematopoietic stem cells from cord blood. Greater than 1 million cord blood units have been processed and stored worldwide since its launch.
2007: Awarded FDA PMA approval for the CryoSeal FS System that produces fibrin sealant from a surgical patient’s own blood while in the surgical suite.
2013: Merged with the regenerative medicine company TotipotentRx and formed Cesca Therapeutics Inc.; expanding business focus into the regenerative medicine area while maintaining the ThermoGenesis brand as the company’s device division.
2016: Boyalife Group, a global diversified life science holding company, made a strategic investment in the Company and became the largest shareholder.
2017: Acquisition of SynGen Inc., a Sacramento based medical device company that develops buoyancy-activated cell sorting (X-BACS™) technology.
2018: Launched the CAR-TXpress™ Platform, a high efficiency, semi-automated manufacturing platform to support the manufacturing needs of cell and gene therapies, such as chimeric antigen receptor (CAR) T-cell treatments.
2019: Executed a global distribution agreement with CLS, a global Fortune 500 company, to distribute the X-SERIES® cell processing products.
2019: Formed the joint venture ImmuneCyte with Healthbanks Biotech (USA) to provide immune cell banking, and cell-based contract manufacturing services utilizing the CAR-TXpress™ Platform.
Ensure the future benefit of cell and gene therapy to everyone in need through reduction of drug manufacturing cost and increased patient accessibility.
ThermoGenesis collaborates with leading academic institutions and industry partners to develop the best products for their specific processes. Co-developments are welcomed for new applications, or customizing off-the-shelf solutions based on our available technologies. To explore a partnership with ThermoGenesis, please contact our business development team.